Which has better valuation & earnings, INKT or COCP?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A

Is INKT or COCP more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Cocrystal Pharma N/A -150.61% -97.86%

Which has stronger earnings and valuation, COCP or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is COCP or PDSB more profitable?

Cocrystal Pharma's return on equity of -150.61% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% PDS Biotechnology N/A -346.02% -102.36%

Is COCP or HYPD more profitable?

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Hyperion DeFi N/A -91.59% -73.08%

Do analysts recommend COCP or GMTX?

Cocrystal Pharma currently has a consensus target price of $6.00, indicating a potential upside of 500.00%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Cocrystal Pharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, COCP or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is COCP or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Gemini Therapeutics N/A -38.78% -35.88%

Which has stronger valuation and earnings, DWTX or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A

Is DWTX or COCP more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Cocrystal Pharma N/A -150.61% -97.86%

Cocrystal Pharma (COCP) Competitors

$1.00 -0.02 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$0.99 -0.01 (-1.00%)

As of 06:38 PM Eastern

Compare

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

Should you buy Cocrystal Pharma stock or one of its competitors? MarketBeat compares Cocrystal Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cocrystal Pharma include MiNK Therapeutics (INKT), PDS Biotechnology (PDSB), Hyperion DeFi (HYPD), Gemini Therapeutics (GMTX), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry.

How does Cocrystal Pharma compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for MiNK Therapeutics and 1 mentions for Cocrystal Pharma. MiNK Therapeutics' average media sentiment score of 0.67 beat Cocrystal Pharma's score of 0.29 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Positive
Cocrystal Pharma	Neutral

MiNK Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Cocrystal Pharma	N/A	-150.61%	-97.86%

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 187.12%. Cocrystal Pharma has a consensus target price of $6.00, indicating a potential upside of 500.00%. Given Cocrystal Pharma's higher probable upside, analysts clearly believe Cocrystal Pharma is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Summary

Cocrystal Pharma beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to PDS Biotechnology?

Cocrystal Pharma (NASDAQ:COCP) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

PDS Biotechnology is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cocrystal Pharma and Cocrystal Pharma both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.87 beat Cocrystal Pharma's score of 0.29 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
PDS Biotechnology	Very Positive

Cocrystal Pharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Cocrystal Pharma's return on equity of -150.61% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
PDS Biotechnology	N/A	-346.02%	-102.36%

Cocrystal Pharma currently has a consensus target price of $6.00, indicating a potential upside of 500.00%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 749.06%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PDS Biotechnology beats Cocrystal Pharma on 7 of the 12 factors compared between the two stocks.

How does Cocrystal Pharma compare to Hyperion DeFi?

Cocrystal Pharma (NASDAQ:COCP) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Hyperion DeFi had 4 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Hyperion DeFi and 1 mentions for Cocrystal Pharma. Hyperion DeFi's average media sentiment score of 0.75 beat Cocrystal Pharma's score of 0.29 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Hyperion DeFi	Positive

Cocrystal Pharma presently has a consensus price target of $6.00, indicating a potential upside of 500.00%. Hyperion DeFi has a consensus price target of $5.65, indicating a potential upside of 124.21%. Given Cocrystal Pharma's higher probable upside, equities analysts plainly believe Cocrystal Pharma is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Hyperion DeFi's return on equity of -91.59% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Hyperion DeFi	N/A	-91.59%	-73.08%

Cocrystal Pharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

Cocrystal Pharma has higher earnings, but lower revenue than Hyperion DeFi. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Hyperion DeFi	$810K	47.16	-$45.31M	-$9.95	N/A

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Hyperion DeFi beats Cocrystal Pharma on 10 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Gemini Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Cocrystal Pharma currently has a consensus target price of $6.00, indicating a potential upside of 500.00%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Cocrystal Pharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Gemini Therapeutics. Cocrystal Pharma's average media sentiment score of 0.29 beat Gemini Therapeutics' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Gemini Therapeutics	Neutral

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gemini Therapeutics' return on equity of -38.78% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Cocrystal Pharma beats Gemini Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Cocrystal Pharma. Dogwood Therapeutics' average media sentiment score of 1.43 beat Cocrystal Pharma's score of 0.29 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dogwood Therapeutics	Positive
Cocrystal Pharma	Neutral

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 705.37%. Cocrystal Pharma has a consensus price target of $6.00, suggesting a potential upside of 500.00%. Given Dogwood Therapeutics' higher possible upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics' return on equity of -108.57% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Dogwood Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

Summary

Dogwood Therapeutics beats Cocrystal Pharma on 8 of the 11 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.79M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.37	18.99	24.49	23.62
Price / Sales	N/A	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	2.17	8.00	10.43	6.70
Net Income	-$8.83M	$23.89M	$3.56B	$337.26M
7 Day Performance	-5.66%	-3.49%	-1.38%	-1.41%
1 Month Performance	-30.56%	1.02%	0.86%	1.15%
1 Year Performance	-37.89%	34.39%	19.43%	22.61%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	2.8646 of 5 stars	$1.00 -2.0%	$6.00 +500.0%	-38.2%	$13.79M	N/A	N/A	10	Analyst Upgrade Gap Up
INKT MiNK Therapeutics	3.3331 of 5 stars	$11.99 -3.2%	$35.00 +192.0%	+62.6%	$60.78M	N/A	N/A	30	Gap Up
PDSB PDS Biotechnology	3.5283 of 5 stars	$1.19 +3.9%	$9.00 +659.5%	-39.8%	$60.28M	N/A	N/A	20
HYPD Hyperion DeFi	4.1563 of 5 stars	$3.70 -4.2%	$5.88 +58.9%	-40.0%	$58.51M	$1.04M	N/A	40	Analyst Forecast Gap Down
GMTX Gemini Therapeutics	N/A	$71.97 +3.4%	N/A	+31.5%	$58.49M	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

How does Cocrystal Pharma compare to MiNK Therapeutics?

Summary

How does Cocrystal Pharma compare to PDS Biotechnology?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Summary

How does Cocrystal Pharma compare to Gemini Therapeutics?

Summary

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. INKT, PDSB, HYPD, GMTX, and DWTX

How does Cocrystal Pharma compare to MiNK Therapeutics?

Does the media prefer INKT or COCP?

Is INKT or COCP more profitable?

Do analysts prefer INKT or COCP?

Which has more volatility & risk, INKT or COCP?

Do institutionals & insiders believe in INKT or COCP?

Which has better valuation & earnings, INKT or COCP?

Summary

How does Cocrystal Pharma compare to PDS Biotechnology?

Which has stronger earnings and valuation, COCP or PDSB?

Do institutionals and insiders believe in COCP or PDSB?

Does the media favor COCP or PDSB?

Which has more risk and volatility, COCP or PDSB?

Is COCP or PDSB more profitable?

Do analysts recommend COCP or PDSB?

Summary

How does Cocrystal Pharma compare to Hyperion DeFi?

Does the media favor COCP or HYPD?

Do analysts recommend COCP or HYPD?

Is COCP or HYPD more profitable?

Which has more volatility and risk, COCP or HYPD?

Which has better valuation and earnings, COCP or HYPD?

Do institutionals & insiders believe in COCP or HYPD?

Summary

How does Cocrystal Pharma compare to Gemini Therapeutics?

Do analysts recommend COCP or GMTX?

Which has higher earnings & valuation, COCP or GMTX?

Which has more volatility & risk, COCP or GMTX?

Does the media refer more to COCP or GMTX?

Do institutionals and insiders believe in COCP or GMTX?

Is COCP or GMTX more profitable?

Summary

How does Cocrystal Pharma compare to Dogwood Therapeutics?

Does the media prefer DWTX or COCP?

Do insiders and institutionals have more ownership in DWTX or COCP?

Do analysts rate DWTX or COCP?

Is DWTX or COCP more profitable?

Which has more risk & volatility, DWTX or COCP?

Which has stronger valuation and earnings, DWTX or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools